title: Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study.
authors.affiliation: Rheumatology Unit, Department of Internal Medicine, University of Pisa, 56126, Pisa, Italy, sara.talarico76@gmail.com.
authors.forename: Rosaria
authors.initials: R
authors.lastname: Talarico
authors.forename: Laura
authors.initials: L
authors.lastname: Bazzichi
authors.forename: Anna
authors.initials: A
authors.lastname: d'Ascanio
authors.forename: Claudia
authors.initials: C
authors.lastname: Ferrari
authors.forename: Elena
authors.initials: E
authors.lastname: Elefante
authors.forename: Chiara
authors.initials: C
authors.lastname: Tani
authors.forename: Chiara
authors.initials: C
authors.lastname: Baldini
authors.forename: Marta
authors.initials: M
authors.lastname: Mosca
authors.forename: Stefano
authors.initials: S
authors.lastname: Bombardieri
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D001528:Behcet Syndrome / Q000150:complications* / Q000628:therapy*; D001688:Biological Products / Q000009:adverse effects*; D001691:Biological Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007239:Infections / Q000150:complications* / Q000209:etiology; D007249:Inflammation; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012107:Research Design; D012306:Risk; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D000069285:Infliximab; D000068879:Adalimumab